Anastrozole vs Exemestane
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Anastrozole and Exemestane carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Anastrozole Exemestane
Weight 293.37 Da 296.40 Da
Half-life ~40-50 hours ~24 hours
Type Nonsteroidal aromatase inhibitor (triazole derivative) Steroidal aromatase inhibitor (irreversible, suicide inhibitor)
Key Benefits
Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
Side Effects
Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Research Evidence
Anastrozole Exemestane
Status FDA Approved FDA Approved
References 5 studies 5 studies
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.